Results 21 to 30 of about 1,153,662 (221)

Learning in multi-agent systems [PDF]

open access: yes, 2001
In recent years, multi-agent systems (MASs) have received increasing attention in the artificial intelligence community. Research in multi-agent systems involves the investigation of autonomous, rational and flexible behaviour of entities such as ...
Alonso, E.   +14 more
core   +1 more source

TITANIUM NANOPARTICLES CONJUGATED WITH STREPTOKINASE AS A MODIFIED THROMBOLYTIC AGENT [PDF]

open access: yes, 2020
Objective: Blood clots are the main cause of death worldwide by stroke and myocardial infarction. Streptokinase a thrombolytic agent that is used in the treatment of circulatory disorders.
ABED, HAYDER H.   +2 more
core   +1 more source

Endovascular Treatment of Cerebral Venous Sinus Thrombosis

open access: yesPediatric Neurology Briefs, 2013
Investigators at Frenchay Hospital, Bristol, UK, retrospectively reviewed case notes and imaging in 9 consecutive children (age range 18 months to 16 years) with cerebral venous sinus thrombosis (CVST) who were treated using endovascular methods after ...
J Gordon Millichap
doaj   +1 more source

Enhanced thrombolysis by endovascular low-frequency ultrasound with bifunctional microbubbles in venous thrombosis: in vitro and in vivo study

open access: yesFrontiers in Bioengineering and Biotechnology, 2022
There is a need to improve the efficacy and safety of endovascular techniques in venous thrombotic diseases, and microbubble enhanced sonothrombolysis is a promising approach.
Zhaojian Wang   +10 more
doaj   +1 more source

From SMART to agent systems development [PDF]

open access: yes, 2005
In order for agent-oriented software engineering to prove effective it must use principled notions of agents and enabling specification and reasoning, while still considering routes to practical implementation.
Ashri, Ronald   +9 more
core   +1 more source

In Hospital Atrial Fibrillation is a Predictor of Long Term Stroke Event among Patients with Acute Myocardial Infarction

open access: yesMajalah Kardiologi Indonesia, 2013
Background. Atrial fibrillation (AF) is a common arrhythmia after acute myocardial infarction (AMI).Mortality in AMI patients with AF also been shown to be up to twice as high as for those without AF.
Manoefris Kasim   +2 more
doaj   +1 more source

Evaluation of clinical efficacy of streptokinase by comparison with the thrombolytic agent on animal model [PDF]

open access: yesBrazilian Journal of Biology
Cardiovascular disorders, including acute myocardial infarction (AMI), often lead to blood clot formation, impacting blood circulation. Streptokinase, a cost-effective and widely available thrombolytic agent, is crucial in treating thrombosis. This study
S. Yousaf   +6 more
doaj   +1 more source

CLINICAL RESULTS OF THROMBOLYTIC THERAPY WITH ALTEPLASE AND TENECTEPLASE IN PATIENTS WITH MYOCARDIAL INFARCTION

open access: yesРациональная фармакотерапия в кардиологии, 2015
Aim. To evaluate the clinical results of thrombolytic therapy with thrombolytics (alteplase, tenecteplase) in patients with ST segment elevation myocardial infarction (STEMI). Material and methods.
L. A. Bondarenko   +4 more
doaj   +3 more sources

CLINICAL CASE OF THROMBOLYTIC THERAPY OF RECURRENT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PATIENT WITH LONG HISTORY OF ISCHEMIC HEART DISEASE

open access: yesРациональная фармакотерапия в кардиологии, 2016
Presented case report demonstrates the efficacy and safety of hospital use of thrombolytic agent Fortelizin in pharmaco-invasive strategy for the treatment of a patient with acute myocardial infarction and with a long history of ischemic heart disease ...
N. T. Vatutin   +3 more
doaj   +1 more source

A Methodology for Agent-Oriented Analysis and Design

open access: yes, 1999
This paper presents a methodology for agent-oriented analysis and design. The methodology is general, in that it is applicable to a wide range of multi-agent systems, and comprehensive, in that it deals with both the macro-level (societal) and the micro ...
Kinny, D.   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy